Sanofi: Dupixent Surpasses 4 Billion Euros, EPS Climbs by 14%

Strong Performance in Q1 2026

First quarter 2026 revenue grew by 13.6% at constant exchange rates, primarily supported by launches in the Pharma portfolio and recent acquisitions by the group. Dupixent, the main growth driver, recorded revenues exceeding 4 billion euros, with an increase of 30.8%. Net earnings per share from operations reached 1.88 euros, up by 14.0%. This EPS growth surpasses that of the revenue, reflecting a more moderate increase in operational expenses, which only rose by 7.0%. This discrepancy between revenue dynamics and expense dynamics indicates a positive operational leverage effect.

Regulatory Approvals and Clinical Advances

Sanofi secured five new regulatory approvals during the quarter, all in the field of immunology, strengthening its position in a strategic therapeutic area. The company also reported positive results from a phase 3 study of venglustat in rare diseases, as well as encouraging data from phase 2 studies of lunsekimig in respiratory diseases. These milestones confirm the sustained activity of the group's clinical pipeline.

2026 Outlook and Management Transition

Sanofi confirms its outlook for the full year 2026: expected sales growth in the upper single digits, accompanied by net earnings per share growth slightly above that of sales at constant exchange rates, leading to profitable growth. Additionally, Belén Garijo will assume the role of CEO starting May 2026, succeeding Olivier Charmeil who is currently the interim CEO. This leadership transition occurs in a context of positive operational momentum and reaffirmation of annual goals.